Immunodominance and tumor escape

Area of Science:

• Cancer immunology
• Tumor antigen presentation
• Immunotherapy

Background:

• Cancers express tumor-specific and tumor-associated antigens, eliciting host immune responses.
• Immunodominance can lead to the selection of antigen loss variants and prevent responses to new antigens.
• Tumor progression may involve the retention of essential tumor-specific antigens.

Purpose of the Study:

• To investigate how immunodominance contributes to cancer immune escape.
• To explore mechanisms by which cancer cells evade host immunity.
• To identify strategies for overcoming cancer immune evasion.

Main Methods:

• Analysis of tumor antigen expression in mouse and human cancers.
• Study of host immune responses and immunodominance.
• Investigation of antigen loss variants and tumor progression.
• Evaluation of cross-presentation of tumor antigens by MHC Class I alleles.
• Assessment of immunization strategies using selected cancer cell variants.

Main Results:

• Immunodominance can result in successive selection of heritable antigen loss variants.
• Immunodominance may prevent responses to new tumor-specific antigens arising during progression.
• Some tumor-specific antigens are retained for malignant phenotype survival.
• Loss of an MHC Class I allele can be overcome by cross-presentation, sustaining immunodominance and preventing responses to secondary antigens.

Conclusions:

• Immunodominance is a key mechanism for cancer immune escape.
• Targeting immunodominant antigens can break immune evasion.
• Immunization with cancer cell variants lacking immunodominant antigens can prevent cancer escape from host immunity.